Business Context and Reporting Period
Jin Medical International Ltd., a foreign private issuer headquartered in Jiangsu Province, China, filed this Form 6-K for May 2024. The filing reports the Company’s regained compliance with Nasdaq’s periodic filing requirement.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other operating or financial metrics. It states that the Company filed its fiscal year 2023 Form 20-F with the SEC on April 26, 2024.
Material Changes Versus the Prior Period
- On March 28, 2024, the Nasdaq Hearings Panel granted continued listing subject to the Company filing its 2023 Form 20-F by May 20, 2024.
- The Company filed the 2023 Form 20-F on April 26, 2024.
- On May 9, 2024, Nasdaq notified the Company that it had regained compliance with Listing Rule 5250(c).
Outlook, Risks, Contingencies, and Unusual Items
- Nasdaq will monitor the Company’s compliance with the filing requirement through May 9, 2025.
- If the Company becomes non-compliant during the monitoring period, it will not be permitted to submit a compliance plan or receive additional time from Nasdaq staff to regain compliance.
- Instead, Nasdaq staff would be required to issue a delist determination, after which the Company could request a new hearing before a Nasdaq panel.
- The filing provides no financial guidance or operational outlook.
Investor Verification Items
- Review the fiscal year 2023 Form 20-F filed on April 26, 2024 for the Company’s financial results, liquidity, debt, risks, and business outlook.
- Monitor the Company’s future periodic filings through May 9, 2025 to confirm continued Nasdaq compliance.
- Verify whether any subsequent Nasdaq notices or delisting proceedings have occurred.